InvestorsHub Logo
Followers 48
Posts 9781
Boards Moderated 1
Alias Born 01/31/2008

Re: James salmon post# 441806

Thursday, 12/07/2023 4:45:17 AM

Thursday, December 07, 2023 4:45:17 AM

Post# of 462982
More competition for AVXL

AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.

The deal is AbbVie's second major acquisition announced in the last two weeks, after the pharmaceutical giant announced Nov. 30 it would acquire ImmunoGen for $10 billion.

Cerevel is currently developing potential candidates to treat schizophrenia, Parkinson's disease and mood disorders.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News